zilovertamab,ibrutinib
oncternal therapeutics,janssen,abbvie,merck
['zilovertamab', 'ibru', 'oncternal', '$onct']
$onct new article : oncternal therapeutics presents rationale and plans for its registrational phase 3 study evaluating zilovertamab in combination with ibrutinib at the eha 2022 congress get all the latest $onct related news here : 
We'll make staying up-to-date on financials news easy for you. Discover how https://t.co/qYtx6dQ3dV revolutionizes how you gather financial related news